Lilly to invest $4.5 billion in Indiana

Eli Lilly and Company plans to invest $4.5 billion in a new drug research and development facility in Lebanon, Indiana. The center will be in the LEAP Research and Innovation District, where Lilly will research new ways to produce medicines and scale up the manufacture of drugs for clinical trials. The company makes the blockbuster antidiabetes and weight-loss drugs Mounjaro and Zepbound, which are glucagon-like peptide-1 (GLP-1) agonists. It has several other obesity and neurological disease drugs in development. Lilly has already invested billions of dollars to ramp up the production of tirzepatide, the active ingredient in two of its GLP-1 drugs.